Granulocyte-colony stimulating factor (G-CSF)
Granulocyte-colony stimulating factor (G-CSF) is a pharmaceutical drug with 7 clinical trials. Historical success rate of 85.7%.
Success Metrics
Based on 6 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
3
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
85.7%
6 of 7 finished
14.3%
1 ended early
0
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden
An Evaluation of the Spectra Optia CMNC Collection Procedure
Clinical Trials (7)
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden
An Evaluation of the Spectra Optia CMNC Collection Procedure
Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7